Peter J. Van Veldhuizen

5.6k total citations · 1 hit paper
96 papers, 3.6k citations indexed

About

Peter J. Van Veldhuizen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Peter J. Van Veldhuizen has authored 96 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 49 papers in Oncology and 31 papers in Molecular Biology. Recurrent topics in Peter J. Van Veldhuizen's work include Prostate Cancer Treatment and Research (29 papers), Renal cell carcinoma treatment (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Peter J. Van Veldhuizen is often cited by papers focused on Prostate Cancer Treatment and Research (29 papers), Renal cell carcinoma treatment (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Peter J. Van Veldhuizen collaborates with scholars based in United States, France and Canada. Peter J. Van Veldhuizen's co-authors include Sushanta K. Banerjee, Snigdha Banerjee, Suman Kambhampati, Primo N. Lara, Maha Hussain, Raj Sadasivan, Philip C. Mack, Nicholas J. Vogelzang, Ian M. Thompson and Smita Mehta and has published in prestigious journals such as JAMA, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Peter J. Van Veldhuizen

96 papers receiving 3.6k citations

Hit Papers

Management of Metastatic Clear Cell Renal Cell Carcinoma:... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
    2022 175 citations Peter J. Van Veldhuizen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter J. Van Veldhuizen United States 34 1.4k 1.4k 1.3k 827 374 96 3.6k
Andries M. Bergman Netherlands 33 1.8k 1.3× 1.6k 1.1× 1.6k 1.3× 797 1.0× 725 1.9× 158 4.5k
Nithya Ramnath United States 33 1.5k 1.1× 1.4k 1.0× 1.7k 1.3× 666 0.8× 257 0.7× 123 4.1k
Yang Lü United States 35 1.9k 1.3× 1.9k 1.4× 971 0.7× 906 1.1× 491 1.3× 171 4.5k
Kostas Syrigos Greece 30 1.6k 1.2× 1.0k 0.7× 1.1k 0.8× 428 0.5× 352 0.9× 114 3.3k
Noriaki Sunaga Japan 37 1.7k 1.2× 2.4k 1.7× 1.6k 1.2× 820 1.0× 279 0.7× 153 4.7k
Qinghua Zhou China 29 1.5k 1.1× 1.2k 0.8× 1.7k 1.3× 926 1.1× 333 0.9× 215 3.8k
Gerald A. Soff United States 41 962 0.7× 2.1k 1.5× 683 0.5× 1.3k 1.5× 516 1.4× 137 5.7k
Tsu-Yi Chao Taiwan 31 2.3k 1.6× 1.5k 1.1× 2.0k 1.5× 827 1.0× 285 0.8× 102 4.4k
Gee‐Chen Chang Taiwan 31 1.4k 1.0× 1.6k 1.1× 1.6k 1.2× 784 0.9× 155 0.4× 55 3.3k

Countries citing papers authored by Peter J. Van Veldhuizen

Since Specialization
Citations

This map shows the geographic impact of Peter J. Van Veldhuizen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Van Veldhuizen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Van Veldhuizen more than expected).

Fields of papers citing papers by Peter J. Van Veldhuizen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Van Veldhuizen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Van Veldhuizen. The network helps show where Peter J. Van Veldhuizen may publish in the future.

Co-authorship network of co-authors of Peter J. Van Veldhuizen

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Van Veldhuizen. A scholar is included among the top collaborators of Peter J. Van Veldhuizen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Van Veldhuizen. Peter J. Van Veldhuizen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zwier, Raphaël, et al.. (2024). Enabling high-sensitivity live single-cell mass spectrometry using an integrated electrical lysis and nano electrospray ionization interface. Analytica Chimica Acta. 1324. 343068–343068. 2 indexed citations
2.
Ellis, Shellie D., Riha Vaidya, Joseph M. Unger, et al.. (2022). Access to urologists for participation in research: An analysis of NCI's Community Oncology Research Program landscape survey. Contemporary Clinical Trials Communications. 29. 100981–100981. 2 indexed citations
3.
Das, Bhaskar C., et al.. (2022). Magmas Inhibition in Prostate Cancer: A Novel Target for Treatment-Resistant Disease. Cancers. 14(11). 2732–2732. 5 indexed citations
4.
Unger, Joseph M., Katherine Griffin, Gary Donaldson, et al.. (2018). Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). Journal of Patient-Reported Outcomes. 2(1). 27–27. 7 indexed citations
5.
Rodriguez, Robert M., et al.. (2015). Metastatic Papillary Renal Cell Carcinoma Regression After Cytoreductive Nephrectomy. Urology. 85(2). 283–287. 4 indexed citations
6.
7.
Dusing, Reginald, Sue‐Min Lai, Gordon L. Grado, et al.. (2014). Prostate-Specific Antigen and Prostate-Specific Antigen Velocity as Threshold Indicators in 11C-Acetate PET/CTAC Scanning for Prostate Cancer Recurrence. Clinical Nuclear Medicine. 39(9). 777–783. 13 indexed citations
8.
Kambhampati, Suman, Roger A. Rajewski, Inamul Haque, et al.. (2013). A Second-Generation 2-Methoxyestradiol Prodrug Is Effective against Barrett's Adenocarcinoma in a Mouse Xenograft Model. Molecular Cancer Therapeutics. 12(3). 255–263. 22 indexed citations
9.
10.
Patel, Vijay, Emma Borrego-Diaz, Kun Wang, et al.. (2012). Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer. Lung Cancer. 77(2). 252–259. 33 indexed citations
11.
12.
Karan, Dev, Seema Dubey, Peter J. Van Veldhuizen, et al.. (2011). Dual Antigen Target-Based Immunotherapy for Prostate Cancer Eliminates the Growth of Established Tumors in Mice. Immunotherapy. 3(6). 735–746. 17 indexed citations
13.
14.
Veldhuizen, Peter J. Van, Gibanananda Ray, Snigdha Banerjee, et al.. (2007). 2‐Methoxyestradiol modulates β‐catenin in prostate cancer cells: A possible mediator of 2‐methoxyestradiol‐induced inhibition of cell growth. International Journal of Cancer. 122(3). 567–571. 18 indexed citations
15.
Ray, Gibanananda, Gopal Dhar, Peter J. Van Veldhuizen, et al.. (2006). Modulation of Cell-Cycle Regulatory Signaling Network by 2-Methoxyestradiol in Prostate Cancer Cells Is Mediated through Multiple Signal Transduction Pathways. Biochemistry. 45(11). 3703–3713. 38 indexed citations
16.
Veldhuizen, Peter J. Van, Sarah A. Taylor, Stephen K. Williamson, & Betty M. Drees. (2000). TREATMENT OF VITAMIN D DEFICIENCY IN PATIENTS WITH METASTATIC PROSTATE CANCER MAY IMPROVE BONE PAIN AND MUSCLE STRENGTH. The Journal of Urology. 187–187. 11 indexed citations
17.
Veldhuizen, Peter J. Van, et al.. (1996). Urokinase-Type Plasminogen Activator Expression in Human Prostate Carcinomas. The American Journal of the Medical Sciences. 312(1). 8–11. 15 indexed citations
18.
Veldhuizen, Peter J. Van, Raj Sadasivan, Fernando U. Garcia, Mark S. Austenfeld, & Ronald L. Stephens. (1993). Mutant p53 expression in prostate carcinoma. The Prostate. 22(1). 23–30. 63 indexed citations
19.
Veldhuizen, Peter J. Van, James R. Neff, Mark D. Murphey, David Bodensteiner, & Barry Skikne. (1993). Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. American Journal of Hematology. 44(4). 243–248. 96 indexed citations
20.
Veldhuizen, Peter J. Van, et al.. (1989). Takayasu arteritis presenting as retinal and vertebrobasilar ischemia.. PubMed. 16(7). 1000–2. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andries M. Bergman Breakdown of academic impact, for papers by Nithya Ramnath Breakdown of academic impact, for papers by Yang Lü Breakdown of academic impact, for papers by Kostas Syrigos Breakdown of academic impact, for papers by Noriaki Sunaga Breakdown of academic impact, for papers by Qinghua Zhou Breakdown of academic impact, for papers by Gerald A. Soff Breakdown of academic impact, for papers by Tsu-Yi Chao Breakdown of academic impact, for papers by Gee‐Chen Chang
Rankless by CCL
2026